Cargando…
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellul...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association for the Study of the Liver
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760005/ https://www.ncbi.nlm.nih.gov/pubmed/29151326 http://dx.doi.org/10.3350/cmh.2017.0108 |